EUVIMEDEUVIMED entdecken
Crossref

Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma

Matteo S. Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark Faries, Thuy T. Tran, C. Lance Cowey und 28 weitere

JCO Oncology Advances · 2026-01 · 3 (1)

DOI: 10.1200/oa-25-00008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Matteo S. Carlino und 39 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Primary analysis of KEYNOTE-942 (ClinicalTrials.gov identifier: NCT03897881 ) demonstrated prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) for the individualized neoantigen therapy intismeran autogene (intismeran; formerly mRNA-4157 or V940) with pembrolizumab versus pembrolizumab alone in high-risk resected melanoma. This update provides an additional year of follow-up to assess longer-term efficacy/safety. METHODS KEYNOTE-942 is a phase IIb study in patients with completely resected high-risk (stage IIIB to IV) cutaneous melanoma who were randomly assigned to receive either intismeran plus pembrolizumab or pembrolizumab alone. The primary end point was RFS; secondary end points included DMFS and safety/tolerability. Overall survival and biomarker data were exploratory. RESULTS With a median follow-up of approximately 3 years, and a minimum of approximately 2 years (median [range] 34.9 [25.1-51.0] months), the combination continued to demonstrate improvement in RFS (hazard ratio [HR], 0.510 [80% CI, 0.351 to 0.743]) and DMFS (HR, 0.384 [80% CI, 0.227 to 0.650]) compared with pembrolizumab. The safety profile was consistent with earlier findings. Most adverse events (AEs) were low-grade, with serious AEs, immune-related AEs, and grade 3/4 events comparable between the arms and no grade 4/5 events related to intismeran. CONCLUSION Intismeran plus pembrolizumab significantly prolongs RFS and DMFS compared with pembrolizumab alone for the adjuvant treatment of resected high-risk melanoma.

Zitieren

APA

Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G. T., Luke, J. J., …, & Brown, M. (2026). Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology Advances, 3(1). https://doi.org/10.1200/oa-25-00008

Vancouver

Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, et al. Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology Advances. 2026;3(1). doi:10.1200/oa-25-00008

BibTeX
@article{Carlino2026,
  author = {Carlino, Matteo S. and Khattak, Adnan and Meniawy, Tarek and Ansstas, George and Taylor, Matthew H. and Kim, Kevin B. and McKean, Meredith and Long, Georgina V. and Sullivan, Ryan J. and Faries, Mark and Tran, Thuy T. and Cowey, C. Lance and Pecora, Andrew and Shaheen, Montaser and Segar, Jennifer and Medina, Theresa and Atkinson, Victoria and Gibney, Geoffrey T. and Luke, Jason J. and Thomas, Sajeve and Buchbinder, Elizabeth I. and Hamid, Omid and Weber, Jeffrey S. and Mooradian, Meghan J. and Howle, Julie and Khan, Azim and Huang, Mo and Healy, Jane and Morrissey, Manju and Feldman, Igor and Sehgal, Vasudha and Lu, Min and Rao, Anjali and Zheng, Wei and Srinivasan, Lakshmi and Mao, Huzhang and Guo, Jia and Zhu, Lili and Posadas, Tracey and Brown, Michelle},
  title = {Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1200/oa-25-00008}
}
Kostenlos starten →